Dropping two drug candidates puts Genmab in a better position, says CEO

Genmab made a rare move during Q3 by scrapping two candidates. However, neither CEO Jan van de Winkel nor a Sydbank analyst think the decision will have much of an impact on the company's future.

CEO of Genmab Jan van de Winkel | Photo: PR/Genmab

It isn't every day that biotech company Genmab has to abandon a drug under development.

However, this is exactly what happened to not just one but two candidates during Q3, as revealed in an otherwise positive financial report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs